Diarrhea News and Research

Latest Diarrhea News and Research

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.

5 Jun 2012

ViroPharma initiates maribavir Phase 2 program for CMV infections

ViroPharma Incorporated today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients.

4 Jun 2012

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

4 Jun 2012

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.

4 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).

4 Jun 2012

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

2 Jun 2012

Cera announces new citrus ready-to-drink oral rehydration solution

Cera Products is proud to announce its new CeraLyte-70 Citrus Ready to Drink in a 500 ml environmentally green container with a re-closeable top and a long shelf-life. No mixing is needed, saving health care staff time when fast patient hydration is needed.

2 Jun 2012

UV disinfection may reduce CDI in hospitals and LTCFs

In a recently published article, "Decontamination with Ultraviolet Radiation to Prevent Recurrent Clostridium difficile Infection in 2 Roommates in a Long-Term Care Facility" (Infection Control and Hospital Epidemiology, 05/2012), researchers shared the results of a trial that used Tru-D SmartUVC to prevent coincident recurrent CDI episodes in roommates in a Long-Term Care Facility (LTCF).

2 Jun 2012

LDK378 compound well-tolerated in patients with ALK+ NSCLC

A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib-the only approved ALK inhibitor. Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.

2 Jun 2012

First study to correlate dietary fiber intake with inflammatory markers in adolescents

Adolescents who don't eat enough fiber tend to have bigger bellies and higher levels of inflammatory factors in their blood, both major risk factors for cardiovascular disease and diabetes, researchers report.

2 Jun 2012

Zinc supplementation in young children with serious infections significantly lowers risk of treatment failure

Treating young children with suspected serious bacterial infection with zinc in addition to standard antibiotics significantly reduces the likelihood of treatment failure, according to new research published Online First in The Lancet. In 2010, worldwide, infections were responsible for nearly two-thirds of deaths in children under 5, with around two-fifths of deaths occurring within the first month of life.

1 Jun 2012

Diarrhea News and Research

Latest Diarrhea News and Research

Exelixis reports data from cabozantinib phase 3 trial on MTC

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Takeda announces updated results from orteronel phase 2 study on nmCRPC

ViroPharma initiates maribavir Phase 2 program for CMV infections

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

Onyx announces data from regorafenib Phase 3 trial on GIST

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Cera announces new citrus ready-to-drink oral rehydration solution

UV disinfection may reduce CDI in hospitals and LTCFs

LDK378 compound well-tolerated in patients with ALK+ NSCLC

First study to correlate dietary fiber intake with inflammatory markers in adolescents

Zinc supplementation in young children with serious infections significantly lowers risk of treatment failure

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in